📢 Product Launch Announcement: Tenfoday EM
We are proud to announce the launch of Tenfoday EM, a fixed-dose combination of Tenofovir Disoproxil Fumarate 300 mg and Emtricitabine 200 mg, developed to support first-line antiretroviral therapy in the treatment of HIV-1 infection. This dual-action formulation represents a critical advancement in HIV management, promoting convenience, efficacy, and long-term viral suppression.
🔹 About Tenfoday EM
- Active Ingredients:
- Tenofovir Disoproxil Fumarate (TDF) 300 mg
- Emtricitabine 200 mg
- Therapeutic Class: Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
- Indication:
- For use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients aged 12 years and older.
- Also used as part of pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk individuals.
🔹 Mechanism of Action
Tenofovir and Emtricitabine both act as reverse transcriptase inhibitors, blocking the enzyme required for viral replication. When used together, they offer synergistic action in preventing HIV-1 multiplication, helping to achieve and maintain viral suppression when used as part of a combination regimen.
🔹 Why Choose Tenfoday EM?
✅ Highly Effective Dual Therapy
Proven first-line treatment combination recommended by WHO and CDC.
✅ Once-Daily Dosing
Simplifies adherence and improves patient outcomes.
✅ Trusted Safety Profile
Well-tolerated with decades of clinical use and data.
✅ Part of PrEP Strategy
Valuable in both treatment and prevention of HIV transmission.
✅ Cost-Effective Access
Provides an affordable solution for broad-scale implementation in hospitals and clinics.
🏥 Hospitals, HIV Clinics, ART Centers
- Ideal for institutional care and public health HIV management programs.
👨⚕️ Infectious Disease Specialists, Physicians, General Practitioners
- Suitable for treatment-naïve and treatment-experienced patients.
🧑🤝🧑 Patients Living with HIV or at High Risk of Exposure
- Supports long-term viral suppression and prevention efforts.
🔹 Our Commitment to Innovation
With Tenfoday EM, we reaffirm our dedication to supporting healthcare providers and empowering patients with advanced, evidence-based antiretroviral therapy. This launch reflects our continued pursuit of innovation, reliability, and access in infectious disease care.
Tenfoday EM — Strength Where It Matters Most.
📦 Now Available
To learn more about the prescribing information, and how to incorporate it into HIV treatment protocols, please contact our medical affairs team or visit Tenfoday EM.
